Literature DB >> 12754054

Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase.

Peter Schmidt1, Matthias Schramm, Henning Schröder, Johannes-Peter Stasch.   

Abstract

The heterodimeric heme-protein soluble guanylyl cyclase (sGC) is the only proven receptor for nitric oxide (NO). Recently, two different types of NO-independent soluble guanylyl cyclase stimulators have been discovered. The heme-dependent stimulator 2-[1-[2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5(4-morpholinyl)-4,6-pyrimidinediamine (BAY 41-8543) stimulates the enzyme in a synergistic fashion when combined with NO, requires the presence of the heme group and can be blocked by the soluble guanylyl cyclase inhibitor 1H-(1,2,4)-Oxadiazole-(4,3-a)-quinoxalin-1-one (ODQ). The heme-independent activator 4-[((4-carboxybutyl)[2-[(4-phenethylbenzol) oxy]phenethyl]amino)methyl[benzoic]acid (BAY 58-2667) activates soluble guanylyl cyclase even in the presence of ODQ or rendered heme-deficient. In the present study, BAY 41-8543, BAY 58-2667 and NO strongly increased V(max). Combination of BAY 58-2667 and NO increased V(max) in an additive manner, whereas the synergistic effect of BAY 41-8543 and NO on enzyme activation was reflected in an overadditive increase of V(max). ODQ potentiated V(max) of BAY 58-2667-stimulated soluble guanylyl cyclase. BAY 41-8543 prolonged the half-life of the nitrosyl-heme complex of NO-activated enzyme, an effect that was not observed with BAY 58-2667. These results show the different activation patterns of both compounds and demonstrate their value as tools to investigate the mechanisms that underlie soluble guanylyl cyclase activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754054     DOI: 10.1016/s0014-2999(03)01674-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

Review 1.  Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.

Authors:  George F Lasker; Jason H Maley; Edward A Pankey; Philip J Kadowitz
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

2.  Dynamic ligand exchange in soluble guanylyl cyclase (sGC): implications for sGC regulation and desensitization.

Authors:  Ah-Lim Tsai; Vladimir Berka; Iraida Sharina; Emil Martin
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

Review 3.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 4.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 5.  New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications.

Authors:  John Garthwaite
Journal:  Mol Cell Biochem       Date:  2009-12-11       Impact factor: 3.396

Review 6.  Role of guanylate cyclase modulators in decompensated heart failure.

Authors:  Veselin Mitrovic; Adrian F Hernandez; Markus Meyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

Review 7.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

8.  Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm.

Authors:  Ludovic Waeckel; Cécile Badier-Commander; Thibaut Damery; Ralf Köhler; Patricia Sansilvestri-Morel; Serge Simonet; Christine Vayssettes-Courchay; Heike Wulff; Michel Félétou
Journal:  Pflugers Arch       Date:  2014-11-12       Impact factor: 3.657

9.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

Review 10.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.